SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is presently unknown. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after the booster vaccine dose. Cancer patients o...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2022-08, Vol.171, p.143-149 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | |
| container_start_page | 143 |
| container_title | European journal of cancer (1990) |
| container_volume | 171 |
| creator | Di Giacomo, Anna M. Giacobini, Gianluca Anichini, Gabriele Gandolfo, Claudia D'alonzo, Vincenzo Calabrò, Luana Lofiego, Maria F. Cusi, Maria G. Maio, Michele |
| description | The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is presently unknown. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after the booster vaccine dose.
Cancer patients on treatment at the Center for Immuno-Oncology (CIO) of the University Hospital of Siena, Italy, and health care workers at CIO who had received a booster third dose of mRNA vaccine entered a systematic follow-up monitoring period to prospectively assess their potential risk of SARS-CoV-2 infection. Serological and microneutralization assay were utilized to assess levels of anti-spike IgG, and of neutralizing antibodies to the SARS-CoV-2 Wild Type, Delta and Omicron variants, respectively, after the booster dose and after negativization of the nasopharyngeal swab for those who had developed COVID-19.
Ninety cancer patients with solid tumors on active treatment (Cohort 1) and 30 health care workers (Cohort 2) underwent a booster third dose of mRNA vaccine. After the booster dose, the median value of anti-spike IgG was higher (p = 0.009) in patients than in healthy subjects. Remarkably, 11/90 (12%) patients and 11/30 (37%) healthy subjects tested positive to SARS-CoV-2 infection during the monitoring period. Similar levels of anti-spike IgG and of neutralizing antibodies against all the investigated variants, with geometric mean titers of neutralizing antibodies against the Omicron being the lowest were detected after the booster dose and after COVID-19 in both Cohorts.
The occurrence of SARS-CoV-2 infection we observed in a sizable proportion of booster-dosed cancer patients and in healthy subjects during the Omicron outbreak indicates that highly specific vaccines against SARS-CoV-2 variants are urgently required.
•Patients with solid tumours on active therapy received the third dose of mRNA vaccine to SARS-CoV-2.•Anti-spike and neutralising Ig increased equally in patients and healthy subjects.•COVID-19 risk was prospectively assessed during the Omicron outbreak.•High rates of COVID-19 occurred in booster-dosed patients and healthy subjects.•More specific vaccines for SARS-CoV-2 variants are urgently required. |
| doi_str_mv | 10.1016/j.ejca.2022.05.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9130712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804922002970</els_id><sourcerecordid>2703520083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-575bc0f44b2ead90e41d2412c1c2c82730c7be406a35281fbbabee21579defd3</originalsourceid><addsrcrecordid>eNp9kVFr2zAQx8VoWdN2X2APQ9Bne6ezVckwCiFs3aC00IS9Clk-rzKNlUpOoN--CunK9tInne7-97_jfox9FlAKEJdfh5IGZ0sExBJkCUJ_YDOhVVOAlnjEZtDIptBQNyfsNKUBAJSu4SM7qaQSSiPOmF3O75fFIvwukPuxJzf5MOaIOzs6inxjJ0_jlHjO2lzcEZ8eKNrNM7f9lAX5x9sQ0j7uQiIeer6-v53znXXOj5TO2XFvHxN9en3P2OrH99XiZ3Fzd_1rMb8pXK2rqZBKtg76um6RbNcA1aLDWqATDp1GVYFTLdVwaSuJWvRta1siFFI1HfVddcauDrabbbumzuWlo300m-jXNj6bYL35vzL6B_Mn7EwjKlACs8HFq0EMT1tKkxnCNo55ZYMK8lAAXWUVHlQuhpQi9W8TBJg9FTOYPRWzp2JAmkwlN335d7e3lr8YsuDbQUD5QDtP0SSXz-6o8zEjMV3w7_m_AFobnsE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2703520083</pqid></control><display><type>article</type><title>SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Di Giacomo, Anna M. ; Giacobini, Gianluca ; Anichini, Gabriele ; Gandolfo, Claudia ; D'alonzo, Vincenzo ; Calabrò, Luana ; Lofiego, Maria F. ; Cusi, Maria G. ; Maio, Michele</creator><creatorcontrib>Di Giacomo, Anna M. ; Giacobini, Gianluca ; Anichini, Gabriele ; Gandolfo, Claudia ; D'alonzo, Vincenzo ; Calabrò, Luana ; Lofiego, Maria F. ; Cusi, Maria G. ; Maio, Michele</creatorcontrib><description>The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is presently unknown. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after the booster vaccine dose.
Cancer patients on treatment at the Center for Immuno-Oncology (CIO) of the University Hospital of Siena, Italy, and health care workers at CIO who had received a booster third dose of mRNA vaccine entered a systematic follow-up monitoring period to prospectively assess their potential risk of SARS-CoV-2 infection. Serological and microneutralization assay were utilized to assess levels of anti-spike IgG, and of neutralizing antibodies to the SARS-CoV-2 Wild Type, Delta and Omicron variants, respectively, after the booster dose and after negativization of the nasopharyngeal swab for those who had developed COVID-19.
Ninety cancer patients with solid tumors on active treatment (Cohort 1) and 30 health care workers (Cohort 2) underwent a booster third dose of mRNA vaccine. After the booster dose, the median value of anti-spike IgG was higher (p = 0.009) in patients than in healthy subjects. Remarkably, 11/90 (12%) patients and 11/30 (37%) healthy subjects tested positive to SARS-CoV-2 infection during the monitoring period. Similar levels of anti-spike IgG and of neutralizing antibodies against all the investigated variants, with geometric mean titers of neutralizing antibodies against the Omicron being the lowest were detected after the booster dose and after COVID-19 in both Cohorts.
The occurrence of SARS-CoV-2 infection we observed in a sizable proportion of booster-dosed cancer patients and in healthy subjects during the Omicron outbreak indicates that highly specific vaccines against SARS-CoV-2 variants are urgently required.
•Patients with solid tumours on active therapy received the third dose of mRNA vaccine to SARS-CoV-2.•Anti-spike and neutralising Ig increased equally in patients and healthy subjects.•COVID-19 risk was prospectively assessed during the Omicron outbreak.•High rates of COVID-19 occurred in booster-dosed patients and healthy subjects.•More specific vaccines for SARS-CoV-2 variants are urgently required.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2022.05.018</identifier><identifier>PMID: 35717822</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antibodies ; Antibodies, Neutralizing ; Antibodies, Viral ; Cancer ; Cancer immunotherapy ; Cancer patients ; Cancer vaccines ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Health care ; Health risks ; Humans ; Immunoglobulin G ; Infections ; Medical personnel ; Monitoring ; mRNA ; mRNA Vaccines ; Neoplasms - therapy ; Neutralizing ; Original Research ; Patients ; SARS-CoV-2 ; SARS-CoV-2 infection ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Solid tumors ; Telemedicine ; Tumors ; Vaccines ; Vaccines, Synthetic ; Viral diseases ; Viral Envelope Proteins - genetics</subject><ispartof>European journal of cancer (1990), 2022-08, Vol.171, p.143-149</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Aug 2022</rights><rights>2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-575bc0f44b2ead90e41d2412c1c2c82730c7be406a35281fbbabee21579defd3</citedby><cites>FETCH-LOGICAL-c483t-575bc0f44b2ead90e41d2412c1c2c82730c7be406a35281fbbabee21579defd3</cites><orcidid>0000-0003-2174-0713 ; 0000-0001-9315-2158 ; 0000-0001-8869-8164</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2022.05.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35717822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Giacomo, Anna M.</creatorcontrib><creatorcontrib>Giacobini, Gianluca</creatorcontrib><creatorcontrib>Anichini, Gabriele</creatorcontrib><creatorcontrib>Gandolfo, Claudia</creatorcontrib><creatorcontrib>D'alonzo, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Luana</creatorcontrib><creatorcontrib>Lofiego, Maria F.</creatorcontrib><creatorcontrib>Cusi, Maria G.</creatorcontrib><creatorcontrib>Maio, Michele</creatorcontrib><title>SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is presently unknown. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after the booster vaccine dose.
Cancer patients on treatment at the Center for Immuno-Oncology (CIO) of the University Hospital of Siena, Italy, and health care workers at CIO who had received a booster third dose of mRNA vaccine entered a systematic follow-up monitoring period to prospectively assess their potential risk of SARS-CoV-2 infection. Serological and microneutralization assay were utilized to assess levels of anti-spike IgG, and of neutralizing antibodies to the SARS-CoV-2 Wild Type, Delta and Omicron variants, respectively, after the booster dose and after negativization of the nasopharyngeal swab for those who had developed COVID-19.
Ninety cancer patients with solid tumors on active treatment (Cohort 1) and 30 health care workers (Cohort 2) underwent a booster third dose of mRNA vaccine. After the booster dose, the median value of anti-spike IgG was higher (p = 0.009) in patients than in healthy subjects. Remarkably, 11/90 (12%) patients and 11/30 (37%) healthy subjects tested positive to SARS-CoV-2 infection during the monitoring period. Similar levels of anti-spike IgG and of neutralizing antibodies against all the investigated variants, with geometric mean titers of neutralizing antibodies against the Omicron being the lowest were detected after the booster dose and after COVID-19 in both Cohorts.
The occurrence of SARS-CoV-2 infection we observed in a sizable proportion of booster-dosed cancer patients and in healthy subjects during the Omicron outbreak indicates that highly specific vaccines against SARS-CoV-2 variants are urgently required.
•Patients with solid tumours on active therapy received the third dose of mRNA vaccine to SARS-CoV-2.•Anti-spike and neutralising Ig increased equally in patients and healthy subjects.•COVID-19 risk was prospectively assessed during the Omicron outbreak.•High rates of COVID-19 occurred in booster-dosed patients and healthy subjects.•More specific vaccines for SARS-CoV-2 variants are urgently required.</description><subject>Antibodies</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cancer patients</subject><subject>Cancer vaccines</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Health care</subject><subject>Health risks</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Infections</subject><subject>Medical personnel</subject><subject>Monitoring</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Neoplasms - therapy</subject><subject>Neutralizing</subject><subject>Original Research</subject><subject>Patients</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 infection</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Solid tumors</subject><subject>Telemedicine</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic</subject><subject>Viral diseases</subject><subject>Viral Envelope Proteins - genetics</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVFr2zAQx8VoWdN2X2APQ9Bne6ezVckwCiFs3aC00IS9Clk-rzKNlUpOoN--CunK9tInne7-97_jfox9FlAKEJdfh5IGZ0sExBJkCUJ_YDOhVVOAlnjEZtDIptBQNyfsNKUBAJSu4SM7qaQSSiPOmF3O75fFIvwukPuxJzf5MOaIOzs6inxjJ0_jlHjO2lzcEZ8eKNrNM7f9lAX5x9sQ0j7uQiIeer6-v53znXXOj5TO2XFvHxN9en3P2OrH99XiZ3Fzd_1rMb8pXK2rqZBKtg76um6RbNcA1aLDWqATDp1GVYFTLdVwaSuJWvRta1siFFI1HfVddcauDrabbbumzuWlo300m-jXNj6bYL35vzL6B_Mn7EwjKlACs8HFq0EMT1tKkxnCNo55ZYMK8lAAXWUVHlQuhpQi9W8TBJg9FTOYPRWzp2JAmkwlN335d7e3lr8YsuDbQUD5QDtP0SSXz-6o8zEjMV3w7_m_AFobnsE</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Di Giacomo, Anna M.</creator><creator>Giacobini, Gianluca</creator><creator>Anichini, Gabriele</creator><creator>Gandolfo, Claudia</creator><creator>D'alonzo, Vincenzo</creator><creator>Calabrò, Luana</creator><creator>Lofiego, Maria F.</creator><creator>Cusi, Maria G.</creator><creator>Maio, Michele</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2174-0713</orcidid><orcidid>https://orcid.org/0000-0001-9315-2158</orcidid><orcidid>https://orcid.org/0000-0001-8869-8164</orcidid></search><sort><creationdate>20220801</creationdate><title>SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines</title><author>Di Giacomo, Anna M. ; Giacobini, Gianluca ; Anichini, Gabriele ; Gandolfo, Claudia ; D'alonzo, Vincenzo ; Calabrò, Luana ; Lofiego, Maria F. ; Cusi, Maria G. ; Maio, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-575bc0f44b2ead90e41d2412c1c2c82730c7be406a35281fbbabee21579defd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cancer patients</topic><topic>Cancer vaccines</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Health care</topic><topic>Health risks</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Infections</topic><topic>Medical personnel</topic><topic>Monitoring</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Neoplasms - therapy</topic><topic>Neutralizing</topic><topic>Original Research</topic><topic>Patients</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 infection</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Solid tumors</topic><topic>Telemedicine</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic</topic><topic>Viral diseases</topic><topic>Viral Envelope Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Giacomo, Anna M.</creatorcontrib><creatorcontrib>Giacobini, Gianluca</creatorcontrib><creatorcontrib>Anichini, Gabriele</creatorcontrib><creatorcontrib>Gandolfo, Claudia</creatorcontrib><creatorcontrib>D'alonzo, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Luana</creatorcontrib><creatorcontrib>Lofiego, Maria F.</creatorcontrib><creatorcontrib>Cusi, Maria G.</creatorcontrib><creatorcontrib>Maio, Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Giacomo, Anna M.</au><au>Giacobini, Gianluca</au><au>Anichini, Gabriele</au><au>Gandolfo, Claudia</au><au>D'alonzo, Vincenzo</au><au>Calabrò, Luana</au><au>Lofiego, Maria F.</au><au>Cusi, Maria G.</au><au>Maio, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>171</volume><spage>143</spage><epage>149</epage><pages>143-149</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is presently unknown. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after the booster vaccine dose.
Cancer patients on treatment at the Center for Immuno-Oncology (CIO) of the University Hospital of Siena, Italy, and health care workers at CIO who had received a booster third dose of mRNA vaccine entered a systematic follow-up monitoring period to prospectively assess their potential risk of SARS-CoV-2 infection. Serological and microneutralization assay were utilized to assess levels of anti-spike IgG, and of neutralizing antibodies to the SARS-CoV-2 Wild Type, Delta and Omicron variants, respectively, after the booster dose and after negativization of the nasopharyngeal swab for those who had developed COVID-19.
Ninety cancer patients with solid tumors on active treatment (Cohort 1) and 30 health care workers (Cohort 2) underwent a booster third dose of mRNA vaccine. After the booster dose, the median value of anti-spike IgG was higher (p = 0.009) in patients than in healthy subjects. Remarkably, 11/90 (12%) patients and 11/30 (37%) healthy subjects tested positive to SARS-CoV-2 infection during the monitoring period. Similar levels of anti-spike IgG and of neutralizing antibodies against all the investigated variants, with geometric mean titers of neutralizing antibodies against the Omicron being the lowest were detected after the booster dose and after COVID-19 in both Cohorts.
The occurrence of SARS-CoV-2 infection we observed in a sizable proportion of booster-dosed cancer patients and in healthy subjects during the Omicron outbreak indicates that highly specific vaccines against SARS-CoV-2 variants are urgently required.
•Patients with solid tumours on active therapy received the third dose of mRNA vaccine to SARS-CoV-2.•Anti-spike and neutralising Ig increased equally in patients and healthy subjects.•COVID-19 risk was prospectively assessed during the Omicron outbreak.•High rates of COVID-19 occurred in booster-dosed patients and healthy subjects.•More specific vaccines for SARS-CoV-2 variants are urgently required.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35717822</pmid><doi>10.1016/j.ejca.2022.05.018</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2174-0713</orcidid><orcidid>https://orcid.org/0000-0001-9315-2158</orcidid><orcidid>https://orcid.org/0000-0001-8869-8164</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2022-08, Vol.171, p.143-149 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9130712 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antibodies Antibodies, Neutralizing Antibodies, Viral Cancer Cancer immunotherapy Cancer patients Cancer vaccines Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Health care Health risks Humans Immunoglobulin G Infections Medical personnel Monitoring mRNA mRNA Vaccines Neoplasms - therapy Neutralizing Original Research Patients SARS-CoV-2 SARS-CoV-2 infection Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Solid tumors Telemedicine Tumors Vaccines Vaccines, Synthetic Viral diseases Viral Envelope Proteins - genetics |
| title | SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A43%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20infection%20in%20cancer%20patients%20on%20active%20therapy%20after%20the%20booster%20dose%20of%20mRNA%20vaccines&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Di%20Giacomo,%20Anna%20M.&rft.date=2022-08-01&rft.volume=171&rft.spage=143&rft.epage=149&rft.pages=143-149&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2022.05.018&rft_dat=%3Cproquest_pubme%3E2703520083%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2703520083&rft_id=info:pmid/35717822&rft_els_id=S0959804922002970&rfr_iscdi=true |